0000905718-20-000795.txt : 20200731
0000905718-20-000795.hdr.sgml : 20200731
20200731122601
ACCESSION NUMBER: 0000905718-20-000795
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
FILED AS OF DATE: 20200731
DATE AS OF CHANGE: 20200731
EFFECTIVENESS DATE: 20200731
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: AzurRx BioPharma, Inc.
CENTRAL INDEX KEY: 0001604191
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-372224
FILM NUMBER: 201064780
BUSINESS ADDRESS:
STREET 1: 760 PARKSIDE AVENUE
STREET 2: SUITE 304
CITY: BROOKLYN
STATE: NY
ZIP: 11226
BUSINESS PHONE: 646-699-7855
MAIL ADDRESS:
STREET 1: 760 PARKSIDE AVENUE
STREET 2: SUITE 304
CITY: BROOKLYN
STATE: NY
ZIP: 11226
FORMER COMPANY:
FORMER CONFORMED NAME: BioPharma d'Azur, Inc.
DATE OF NAME CHANGE: 20140331
D
1
primary_doc.xml
X0708
D
LIVE
0001604191
AzurRx BioPharma, Inc.
760 PARKSIDE AVENUE
SUITE 304
BROOKLYN
NY
NEW YORK
11226
646-699-7855
DELAWARE
None
BioPharma d'Azur, Inc.
Corporation
true
Daniel
Schneiderman
760 Parkside Ave.
Suite 304
Brooklyn
NY
NEW YORK
11226
Executive Officer
Gregory
Oakes
760 Parkside Ave.
Suite 304
Brooklyn
NY
NEW YORK
11226
Director
Edward
Borkowski
760 Parkside Ave.
Suite 304
Brooklyn
NY
NEW YORK
11226
Director
Alastair
Riddell
760 Parkside Ave.
Suite 304
Brooklyn
NY
NEW YORK
11226
Director
James
Sapirstein
760 Parkside Ave.
Suite 304
Brooklyn
NY
NEW YORK
11226
Executive Officer
Director
Charles
Casamento
760 Parkside Ave.
Suite 304
Brooklyn
NY
NEW YORK
11226
Director
Vern
Lee
Schramm
760 Parkside Ave.
Suite 304
Brooklyn
NY
NEW YORK
11226
Director
James
Lee
Pennington
760 Parkside Ave.
Suite 304
Brooklyn
NY
NEW YORK
11226
Executive Officer
Biotechnology
Decline to Disclose
- 06b
false
2020-07-16
false
true
true
true
false
0
Alexander Capital, L.P.
40077
None
None
17 STATE STREET
5TH FLOOR
NEW YORK
NY
NEW YORK
10004
All States
false
22800000
22426890
373110
Includes the conversion of certain indebtedness
false
177
1350000
true
0
Alexander Capital, L.P. also received a 1% non-accountable expense allowance and a 3% advisory fee, or approximately $300,000 in aggregate, and was issued warrants exercisable for 1,382,902 shares of common stock, at an exercise price of $1.06 per share.
0
true
Some of the proceeds may be used for general working capital purposes including the payment of salaries and other fees to those listed in Item 3.
false
AzurRx BioPharma, Inc.
/s/ Daniel Schneiderman
Daniel Schneiderman
Chief Financial Officer
2020-07-31